Robot-assisted radical prostatectomy (RARP) including pelvic lymph node dissection (PLND) is the current state of the art in surgical therapy of localized prostate cancer with intermediate or high risk.
Prostate cancer (PC) is the second most commonly diagnosed cancer in males. 68Ga-PSMA PET/CT, a non-invasive diagnostic tool to evaluate PC with prostate-specific membrane antigen (PSMA) expression, has emerged as a more accurate alternative to assess disease staging.
Urologic cancer care needs to be prioritized despite multiple health care restrictions during the coronavirus disease 2019 (COVID-19) pandemic. However, therapies and procedures may be delayed and complicated.
Multifocal occurrence is a main characteristic of urothelial bladder cancer (UBC). Whether urothelial transformation is caused by monoclonal events within the urothelium, or by polyclonal unrelated events resulting in several tumor clones is still under debate.
We evaluated the prognostic value of 10 putative tumor markers by immunohistochemistry in a large multi-institutional cohort of patients with locally advanced urothelial cancer of the bladder (UCB) with the aim to validate their clinical value and to harmonize protocols for their evaluation.
Xpert Bladder Cancer is a detection method developed in recent years, designed with the functions of integrating sample automatically, nucleic acid amplification, and target sequence detection. It is a urine assay targeting five mRNAs (CRH, IGF2, UPK1B, ANXA10, and ABL1).
In the management of bladder tumors bipolarenergy has been used as a common alternative to the conventional monopolar transurethral resection of the bladder (M-TURB). This study aims to examine the clinical efficacy and safety of bipolar versus monopolar TURB tumors (TURBTs).
(UroToday.com) The phase 3 PROfound study1 demonstrated improved overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on prior anti-androgen therapy and harbor deleterious alteration in BRCA1, BRCA2, and ATM. A radiographic progression-free survival benefit was also demonstrated in an overall group of patients harboring a deleterious alteration in selected homologous recombination (HR) genes. In this […]
(UroToday.com) Molecular classifiers for localized prostate cancer such as Decipher® lack prospective randomized controlled data evaluating their clinical utility. The Decipher classifier may be applied to prostate tumor tissue to help predict which patients undergoing prostatectomy may benefit the most from post-operative radiotherapy. To evaluate this, the G-MINOR study enrolled patients with pT3+ and/or surgical […]
(UroToday.com) African American men have a 1.6-1.8-fold higher risk of developing prostate cancer, develop prostate cancer at a younger age, and tend to have more aggressive disease at diagnosis. Disparities in prostate cancer outcomes for these men are likely influenced by both socioeconomic and healthcare access issues, as well as genetic factors. In this study, Dr. Khashab […]
